<DOC>
	<DOCNO>NCT01019681</DOCNO>
	<brief_summary>The purpose study determine whether treatment umbilical cord blood stem cell improve blood flow severely affect leg participant medically refractory non-surgical peripheral vascular disease low extremity .</brief_summary>
	<brief_title>Efficacy Safety Umbilical Cord Blood Injection Critical Limb Ischemia</brief_title>
	<detailed_description>Umbilical cord blood safe alternative source stem cell use decade hematopoietic stem cell transplant malignancy . There also report decreased incidence acute GVHD compare match unrelated donor transplants.A cord blood registry search suitable unit compatibility ABO HLA system . The minimum total nucleate cell dose require would 1.0 x 107/kg , one unit cell procure meet requirement . Although likely transplant cord blood cell reject time , hypothesize remain host 's tissue cell produce release cytokine , growth factor humoral factor might promote vasculogenesis stimulate endogenous stem cell endothelial cell . Since need collect patient 's stem cell , patient 's cardiovascular system subject stress due leukapheresis procedure . No injection exogenous growth factor , associate thrombosis , would require mobilize patient 's stem cell . The procedure could conceivably even perform entirety outpatient basis . A total 25 patient enrol study . Patients follow 24 month procedure evaluation visit one day transplant one month , six , twelve twenty four month post-treatment . The visit one day transplant involve history physical leg exam , CBC chemistry panel evaluate possible infection , adverse event .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Atherosclerotic ischemic peripheral vascular disease Thromboangiitis Obliterans Critical Limb Ischemia ( Fontaine stag III IV ) Participant must match either b 1 . Ankle brachial index ( ABI ) â‰¤ 0.7 2 . Doppler waveform posterior tibial artery dorsalis pedis artery monophasic toe pressure &lt; 30 mmHg . A nonsurgical candidate revascularization e.g . prior vascular reconstruction , inability locate suitable vein grafting , diffuse multi segment disease , extensive infrapopliteal disease amenable vascular graft . Age &gt; 18 year old . The nonindex leg may treat event full fill eligibility criterion exclusion criterion use protocol treatment leg . Patients must maximal tolerated medical therapy PVD include A ) Cessation smoke B ) Referral endocrinologist control HgA1c &lt; 7.0 mg/dl , control hyperlipidemia statin antihyperlipidemic drug indicate , control hypertension indicate C ) Antiplatelet therapy aspirin / cilostazol ( unless medically contraindicate , e.g . bleed allergy ) Popliteal vascular entrapment syndrome Lower extremity infection infect ulcer Hypercoagulable state HIV positive HBsAg positive Uncontrolled arrhythmia , , persistence arrhythmia despite medical therapy Unstable angina Thrombocytopenia &lt; 50,000/ul Leukemia myelodysplasia Allergy E coli product Patients metal body undergo MRIs ( MRA ) . Therefore , patient , cochlear implant , aneurysm clip eligible . Coronary artery stent contraindication . Patients pacemaker still candidate provide normal creatinine ( &lt; 1.1 mg/dl ) receive contrast dye ( allergy ) angiogram instead MRA . MRI/MRA need repeat prior MRA Angiogram Demonstrates inoperable disease . Patients pregnant Poorly control diabetes cause exclusion patient must see endocrinologist good control Current malignancy , except squamous cell basal cell skin cancer think easily control . AST , ALT , bilirubin twice upper limit normal . WBC &lt; 2.5 / ul . Any patient actively bleed , include blood urine dipstick fecal occult blood . Patient chemotherapy immunosuppressive medication steroid , cellcept , cyclosporine , cytoxan , azathioprine , rituxan , humira remicade . Donor HLA homozygous share HLA haplotype recipient ( different donor find ) Patients diagnose Thromboangiitis Obliterans ( Buerger 's Disease ) smokers unwilling unable quit smoke A ) Patients myocardial infarction within last 30 day leave ventricular ejection fraction &lt; 35 % B ) Patients history malignancy last 5 year ( basal cell carcinoma carcinoma situ ) C ) Patients CVA within last 6 month D ) Patients HbA1c level &gt; 7.0 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Cord blood injection peripheral vascular disease</keyword>
</DOC>